Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)

Trial Profile

Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Cisplatin; Fluorouracil
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jul 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
    • 09 Jul 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
    • 03 Jul 2014 Planned End Date changed from 1 Mar 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top